HOUSTON, Dec. 1, 2016 /PRNewswire/ -- ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today announced that two abstracts regarding the Company's lead product candidates, Viralym-C and Viralym-M, were selected for oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California on December 3-6.
"The fact that our results were selected for highly competitive oral presentations speaks to the critical importance of ViraCyte's positive clinical data, as well as the ongoing unmet need of patients following stem cell transplant," said ViraCyte CEO, Dr. Brett Giroir. "We are honored by the opportunity to present our results, as we continue to advance ViraCyte lead products toward pivotal trials and thereafter broad availability for all patients in need."
ViraCyte's ASH Presentations
Viralym-C
Oral Presentation: "Safety and Preliminary Efficacy of 'Ready to Administer' Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection"
Abstract Number: 388
Session Name: Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Phase I Trials
Date: Sunday, December 4, 2016
Presentation Time: 12:45 PM PST
Viralym-M
Oral Presentation: "Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant"
Abstract Number: 501
Session Name: Session: 703. Adoptive Immunotherapy I
Date: Sunday, December 4, 2016
Presentation Time: 5:00 PM PST
About ViraCyte, LLC
ViraCyte is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe life threatening infections. ViraCyte's current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 1 and Phase 2 clinical trials, with effectiveness rates of greater than 90% in patients who have failed conventional therapy. More information can be found at www.viracyte.com.
ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.
SOURCE ViraCyte, LLC